CHONDROSARCOMA IN THE XXI CENTURY

Chondrosarcoma (CHS) is a rare oncopathology, the third most common primary bone tumor after multiple myeloma and osteosarcoma. It accounts for about 25 % of total number sarcomas. CHS mainly affects adults occurs more often in people older than 40 years, children adolescents it less 5 all cases CHS. The sites can be any containing cartilage, but this found pelvis, femur shoulder bones, ribs. are divided: by origin (primary secondary), anatomical site (central — inside marrow canal, peripheral existing osteochondroma, periosteal on surface), histological degrees GI-GII-GIII. WHO classification (2020) includes central normal, secondary peripheral, periosteal, dedifferentiated, mesenchymal clear-cell More 90 conventional tumors low medium malignancy degree, with potential metastasis. caused mutations genes that control growth development. main risk factors patientʼs age, previous radiation, genetic predisposition to oncological diseases. Diagnosis based complex algorithm, which involves collecting patient's complaints, anamnesis, clarifying clinical symptoms, imaging (X-ray, CT, MRI), histopathological picture. biopsy conclusion important establishing final diagnosis. However, there several whose picture similar CHS: enchondroma, chondroblastoma, osteosarcoma, giant cell bone, dedifferentiated liposarcoma, synovial sarcoma. treatment protocol determined results anamnestic data, imaging, results, classification, its subtype. «gold standard» remains surgical removal tumor. Radiation chemotherapy don’t play significant role CHS, require further study. Targeted immunotherapy have certain potential, even high degree resistance traditional chemotherapy.